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Abstract 
Cognitive deterioration and symptom progression occur in schizophrenia over the course of the 
disorder. A dysfunction of the immune system/neuroinflammatory pathways has been linked 
to schizophrenia (SZ). These altered processes in the dorsolateral prefrontal cortex (DLPFC) 
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could contribute to the worsening of the deficits. However, limited studies are available in 
this brain region in elderly population with long-term treatments. In this study, we explore the 
possible deregulation of 21 key genes involved in immune homeostasis, including pro- and anti- 
inflammatory cytokines, cytokine modulators (toll-like receptors, colony-stimulating factors, 
and members of the complement system) and microglial and astroglial markers in the DLPFC 
in elderly chronic schizophrenia. We used quantitative real-time reverse transcriptase poly- 
merase chain reaction (RT-PCR) on extracts from postmortem DLPFC of elderly subjects with 
chronic SZ ( n = 14) compared to healthy control individuals ( n = 14). We report that CSF1R, 
TLR4, IL6, TNF α, TNFRSF1A, IL10, IL10RA, IL10RB, and CD68 were down-regulated in elderly SZ 
subjects. Moreover, we found that the expression levels of all the altered inflammatory genes 
in SZ correlated with the microglial marker CD68 . However, no associations were found with 
the astroglial marker GFAP . This study reveals a decrease in the gene expression of cytokines 
and immune response/inflammation mediators in the DLPFC of elderly subjects with chronic 
schizophrenia, supporting the idea of a dysfunction of these processes in aged patients and 
its possible relationship with active microglia abundance. These findings include elements that 
might contribute to the cognitive decline and symptom progression linked to DLPFC functioning 
at advanced stages of the disease. 
© 2018 Elsevier B.V. and ECNP. All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Schizophrenia (SZ) is a chronic psychiatric disorder char-
acterized by positive (e.g., hallucinations and delusions),
negative (e.g., apathy and impaired motivation), and
cognitive symptoms (e.g., poor performance in executive
functions and attention). The dorsolateral prefrontal cor-
tex (DLPFC) has been reported to contribute to cognitive
deficits (e.g., executive function, working memory, and
attention) ( Sakurai et al., 2015; Teffer and Semendeferi,
2012 ) and negative symptoms ( Toda and Abi-Dargham,
2007 ). Both cognitive deficits and negative symptoms are
present in some people with a first episode psychosis and
ultra-high risk for psychosis, suggesting that these deficits
are present in prodromal phases before the onset of the dis-
ease ( Bora and Murray, 2014; Foussias et al., 2015; Stahl and
Buckley, 2007; Zabala et al., 2010 ). Moreover, some studies
show greater cognitive decline with increased numbers of
relapses ( Xiang et al., 2011 ). Chronic inflammation in the
DLPFC has been suggested as a possible neurobiological ba-
sis of cognitive deterioration over the course of the disease
( Meyer, 2013 ). Supporting the idea that inflammation and
also immune dysfunction play a role in the deficits observed
in SZ are epidemiological, biomolecular, and genetic stud-
ies, and clinical trials with anti-inflammatory drugs ( Gibney
and Drexhage, 2013; Kirkpatrick and Miller, 2013; Müller,
2017 ). Together, these studies raise the possibility that
dysfunction of neuroinflammation and the immune system
might contribute to the deficits observed in the DLPFC
related to the worsening of the symptoms and cognitive
decline in elderly chronic SZ. 
Several lines of evidence from epidemiological studies
have demonstrated that prenatal exposure to maternal im-
mune activation, such as by maternal exposure to infec-
tious diseases during pregnancy, has been associated with
SZ in adult offspring ( Brown, 2011; Brown et al., 2004;
Brown and Derkits, 2010; Canuti et al., 2015; Khandaker
et al., 2013 ). Pro-inflammatory cytokines may be impor-
tant mediators between prenatal exposure and risk of SZPlease cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, htt( Gilmore and Jarskog, 1997; Müller et al., 2015 ). Several
cytokines have been analysed in the serum and/or plasma
of SZ patients, providing evidence of peripheral inflam-
matory changes in SZ. For instance, higher levels of pro-
inflammatory cytokines such as interleukin 6,1 β and TNF α
have been reported in the serum of chronic SZ cases ( Kunz
et al., 2011; Miller et al., 2011; Potvin et al., 2008; Xu et al.,
1994 ). Moreover, a recent meta-analysis of blood cytokine
alterations in schizophrenia revealed a different pattern of
alteration for IL6 and TNF α depending on the clinical status
( Goldsmith et al., 2016 ). 
Inflammation occurs in the brain of individuals with SZ.
In the brain, cytokines are synthesized and secreted mainly
by microglia. The activation of microglial cells is related
with the increase of pro-inflammatory cytokines and free
radicals in SZ ( Monji et al., 2013, 2009 ). Indeed, some an-
tipsychotics possess anti-inflammatory properties by pre-
venting microglial activation, suggesting that the control of
microglia could have a role in the treatment of SZ ( Kato
et al., 2011; Sato-Kasai et al., 2016 ). Using positron emis-
sion tomography (PET) and radio-labeled ligands for the
18kDa translocator protein (TSPO), which is expressed in
the mitochondria of activated microglia, it is possible to
index microglia activation in vivo ( Cagnin et al., 2001 ).
PET studies have shown inconsistent results. Whereas some
PET studies have identified microgliosis in middle-aged pa-
tients within the schizophrenia spectrum who were recover-
ing from psychosis ( Doorduin et al., 2009 ) or in schizophre-
nia patients within the first 5 years of disease onset ( van
Berckel et al., 2008 ), other PET studies have revealed no
microglial activation in patients when compared with con-
trols ( Coughlin et al., 2016; Hafizi et al., 2017; Kenk et al.,
2015; van der Doef et al., 2016 ) or decreased TSPO expres-
sion in patients with first-episode psychosis ( Colleste et al.,
2017 ). Post-mortem studies in mostly chronic middle-age
schizophrenia subjects have demonstrated microglial acti-
vation in SZ ( Bayer et al., 1999; Busse et al., 2012; Radewicz
et al., 2000; van Kesteren et al., 2017; Wierzba-Bobrowicz
et al., 2005 ). However, other studies have not demonstratedt al., Neuroinflammation in the dorsolateral prefrontal cortex in 
ps://doi.org/10.1016/j.euroneuro.2018.12.011 
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Table 1 Demographic, clinical and tissue-related features of cases ( n = 28). 
Schizophrenia ( n = 14) Non-psychiatric controls ( n = 14) Statistic p -value 
Gender Male- 100% ( n = 14) Male- 100% ( n = 14) N/A N/A 
Age at death 76 ± 11 years 71 ± 8 years 1.42; 26 0.1675 
PMD 4.8 ± 2.8 h 5.8 ± 1.9 h 1.23; 26 0. 2307 
pH 6.80 ± 0.23 6.78 ± 0.54 0.16; 26 0.8738 
RIN 7.48 ± 0.49 7.70 ± 0.59 1.08; 26 0.2911 
Age of onset of illness 26 ± 10 N/A N/A N/A 
Duration of illness 50 ± 10 N/A N/A N/A 
Daily AP dose 1 367.14 ± 339.58 N/A N/A N/A 
AP free 28.6% ( n = 4) N/A N/A N/A 
Typical AP 21.4% n = 3) N/A N/A N/A 
Atypical AP 50.0 % ( n = 7) N/A N/A N/A 
PANSS clinical scores ( n = 9) N/A N/A N/A 
Positive 24.63 ± 7.89 N/A N/A N/A 
Negative 25.75 ± 5.63 N/A N/A N/A 
General 50.00 ± 9.40 N/A N/A N/A 
Mean ± standard deviation or relative frequency are shown for each variable; PMD, post-mortem delay; RIN, RNA integrity number; AP, 
antipsychotic; PANSS, Positive and Negative Syndrome Scale; N/A, not applicable. All deaths were due to natural causes. T -statistic and de- 
grees of freedom are shown. The neuropathological categorization of associated sporadic Alzheimer’s disease-related changes (See methods 
section: 0-I, II, III) which was performed according to the Braak and Braak nomenclature adapted for paraffin sections ( Braak et al., 2006; 
Braak and Braak, 1991 ) did not show differences between groups ( χ2 = 0.000; degrees of freedom = 2, p value = 1.00). 1 Last chlorpromazine 
equivalent dose was calculated based on the electronic records of drug prescriptions of the patients. 
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 Arnold et al., 1998; Steiner et al., 2008, 2006 ). Inter-
stingly, recent messenger RNA (mRNA) sequencing (RNA- 
eq) and reverse transcription quantitative PCR studies have 
hown an increase in inflammatory mRNA expression ( IL6, 
NF α, IL8, IL1B and NF-kB ) in post-mortem brains of sub-
ets of patients with SZ ( Fillman et al., 2013; Pandey et al.,
018; Volk et al., 2015 ). Additionally, one of these post-
ortem studies showed that an increase in microgliosis was 
ccompanied by an increase in the cytokine expression lev- 
ls of IL1B in the same region ( Fillman et al., 2013 ). 
Most studies of inflammatory and immune genes have 
ncluded middle-aged subjects with SZ; however, the in- 
ammatory and immune events altered in elderly chronic 
atients in SZ are much less studied. In this study, we
xamine, using a large panel of mRNA probes, the gene 
xpression modulation of cytokines and mediators of the 
mmune response in the dorsolateral prefrontal cortex in 
lderly chronic SZ individuals with long-term treatment. 
he selection of these probes was based on the fact that
he same genes were evaluated in our previous studies of
everal neurodegenerative diseases also with neuroinflam- 
atory components ( Garcia-Esparcia et al., 2014; Llorens 
t al., 2014; López-González et al., 2015a, 2015b; López 
onzález et al., 2016 ). We decided to study the same panel
f genes from inflammatory pathways in schizophrenia in 
he present study with the aim, in the future, of comparing
hese genes across different neuropsychiatric diseases. 
oreover, microglial and astroglial markers were also 
ncluded in this study. Consequently, twenty-one mRNAs, 
ncluding pro- and anti-inflammatory cytokines, cytokine 
odulators (toll-like receptors, colony-stimulating factors, 
nd members of the complement system) and astroglial 
nd microglial markers were assessed in post-mortem 
issue from the dorsolateral prefrontal cortex of elderly SZ 
atients compared to healthy controls. Please cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, htt. Experimental procedures 
.1. Brain human samples 
uman brain tissue was obtained from the neurologic tissue col-
ection of the Parc Sanitari Sant Joan de Déu and the Institute of
europathology Brain Bank (HUB-ICO-IDIBELL Biobank, Barcelona, 
pain) following Spanish legislation guidelines and approval by 
ocal ethics committees. Post-mortem tissue from the dorsolateral 
refrontal cortex of a total of 28 human brains, including 14 control
ases with no history of psychiatric episodes and 14 elderly subjects
ith chronic SZ, were included in the present study. We matched
chizophrenia and control cases by gender, age, post-mortem de-
ay, brain pH, and the histological stage of Alzheimer disease (AD)
 Braak et al., 2006; Braak and Braak, 1991 ). A summary of all the
ases analysed in this study is shown in Table 1 . All SZ subjects were
nstitutionalized donors with long-term illness ( Table 1 ); neither
ontrol nor SZ subjects had a history of neurological diseases. Ex-
erienced clinical examiners interviewed each donor ante-mortem 
o confirm SZ diagnosis according to DSM-IV and ICD-10 criteria. Our
tudy included the following schizophrenia diagnoses: chronic resid- 
al schizophrenia (78.6%, n = 11), chronic paranoid schizophrenia
14.3%, n = 2), and chronic disorganized schizophrenia (7.1%,
 = 1). Moreover, donor subjects were evaluated ante-mortem with
he Positive and Negative Syndrome Scale (PANSS). Only associa-
ions between negative symptoms and gene expression data were
erformed for those subjects with a clinical assessment-to-death
nterval shorter than 48 months ( Table 1 ). The last mean daily
hlorpromazine equivalent dose for the antipsychotic treatment of
atients was based on the electronic records of the last drug
rescriptions administered up to the time of death ( Table 1 ) and
as calculated as previously described ( Gardner et al., 2010 ).
hree of the patients were being medicated with first-generation
ntipsychotics (21.4 %), seven were being medicated with second-
eneration antipsychotics (50%), and four were antipsychotic-free 
28,6%). 
One hemisphere was immediately cut into coronal sections, 1 cm
hick, and selected areas of the encephalon were rapidly dis-
ected, frozen on metal plates over dry ice, placed in individualt al., Neuroinflammation in the dorsolateral prefrontal cortex in 
ps://doi.org/10.1016/j.euroneuro.2018.12.011 
4 I. López-González, R. Pinacho and È. Vila et al. 
ARTICLE IN PRESS 
JID: NEUPSY [m6+; January 5, 2019;0:41 ] 
Table 2 TaqMan probes used for the study of expression of cytokines and mediators of the immune response in the dorsolateral 
prefrontal cortex in control and schizophrenia samples, including probe used for normalization ( XPNPEP1 ). 
Symbol Name of the gene Reference 
GUSB Glucuronidase, beta Hs00939627_m1 
HPRTT1 Hypoxanthine phosphoribosyltransferase 1 Hs02800695_m1 
XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1 Hs00958026_m1 
C1QL1 Complement component 1, q subcomponent 1 Hs00198578_m1 
C1QTNF7 C1q and tumor necrosis factor related protein 7 Hs00230467_m1 
C3AR1 Complement component 3a receptor 1 Hs00377780_m1 
CSF1R Colony stimulating factor 1 receptor Hs00911250_m1 
CSF3R Colony stimulating factor 1 receptor Hs00167918_m1 
TLR4 Toll-like receptor 4 Hs01060206_m1 
TLR7 Toll-like receptor 7 Hs00152971_m1 
IL8 Interleukin 8 Hs00174103_m1 
IL1B Interleukin 1 β Hs01555410_m1 
IL6 Interleukin 6 Hs00985639_m1 
Il6ST Interleukin 6 signal transducer Hs00174360_m1 
TNF α Tumor necrosis factor α Hs01113624_g1 
TNFRSF1A Tumor necrosis factor receptor superfamily member 1a Hs01042313_m1 
IL10 Interleukin 10 Hs00961622_m1 
IL10RA Interleukin 10 receptor α Hs00155485_m1 
IL10RB Interleukin 10 receptor β Hs00988697_m1 
TGB1 Transforming growth factor β1 Hs00998133_m1 
TGB2 Transforming growth factor β2 Hs00234244_m1 
AIF1 Allograft Inflammatory Factor 1 Hs00741549_g1 
CD68 CD68 molecule Hs02836816_g1 
GFAP Glial fibrillary acidic protein Hs00909233_m1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
air-tight plastic bags, numbered with water-resistant ink, and
stored at -80 °C. The other hemisphere was fixed by immersion in 4%
buffered formalin for 3 weeks for morphological studies. The neu-
ropathological categorization of associated sporadic Alzheimer’s
disease-related changes was performed according to the Braak and
Braak classification adapted for paraffin sections ( Braak et al.,
2006; Braak and Braak, 1991 ). Alzheimer’s disease-related pathol-
ogy stages IV-VI of Braak and Braak were not included in the present
study and the occurrence of lower stages was balanced between
control and schizophrenia cases: I or less (SZ:35.7% ( n = 5); Con-
trol: 35.7% ( n = 5)); II (SZ: 50.0% ( n = 7); Control:50.0% ( n = 7)); III
(SZ:14.3% ( n = 2); Control:14.3% ( n = 2)). Specimens of the DLPFC
(Brodmann area BA9), extending from the pial surface to white mat-
ter and only including grey matter, were dissected and stored at
-80 °C. 
2.2. Reverse transcription quantitative PCR (RT-qPCR) 
Total RNA was extracted from the dorsolateral prefrontal cortex
using Trizol reagent (Sigma-Aldrich) following the manufacturer’s
protocol. First strand cDNA was synthesized from 2 μg of RNA using
SuperScript III (Invitrogen). The RNA concentration of each sam-
ple was obtained from A260 measurements with a Nanodrop 2000
(Thermo Scientific, Wilmington, DE). RNA integrity was tested using
an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA).
TaqMan qPCR assays for each gene were conducted in duplicate on
cDNA samples in 384-well optical plates using an ABI Prism 7900
Sequence Detection system (Applied Biosystems, Life Technologies,
Waltham, MA, USA). For each 10 μL TaqMan reaction, 4.5 μL cDNA
diluted 1/10 were mixed with 0.5 μL 20x TaqMan Gene Expression
Assays and 5 μL of 2x TaqMan Universal PCR Master Mix (Applied
Biosystems). The reactions were performed using the following pa-
rameters: 50 °C for 2 min, 95 °C for 10 min, and 40 cycles of 95 °C forPlease cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, htt15 s and 60 °C for 1 min. Finally, TaqMan PCR data were captured
using the Sequence Detection Software (SDS version 2.2, Applied
Biosystems). TaqMan probes used in this study are shown in Table 2 .
Standard deviation and the coefficient of variation of the CT mea-
sures were lower than 0.39 and 1.30, respectively, with the excep-
tion of one determination where the standard deviation was higher
than 1 CT and therefore, excluded from the analysis. Samples were
analysed with the double-delta cycle threshold ( CT) method.
Briefly, the C T of each target mRNA was normalized against that
of the housekeeping gene XPNEP1 (C T target gene -C T XPNEP1 ), thereby
obtaining the difference of CT for each target gene ( C T ). Then,
from each target gene, C T was calculated representing the
C T of each sample normalized to the CT of the internal con-
trol: C T = ( C T GENE (sample) - C T GENE (healthy subject ). Finally, par-
tial fold change was calculated for each target (2 −CT ). The
selection of beta glucuronidase ( GUSB ), X-prolyl aminopeptidase
(aminopeptidaseP) ( XPNPEP1 ), and hypoxanthine-guanine phospho-
ribosyltransferase ( HPRT) as possible housekeeping genes was based
on previous studies in post-mortem brain ( Barrachina et al., 2006;
Durrenberger et al., 2012; Meyronet et al., 2015 ). The most stable
control gene from the three genes was determined using geNorm
and NormFinder software ( Andersen et al., 2004; Vandesompele
et al., 2002 ). XPNEP1 was found to be the most stable gene and
thus selected as the normalization gene for the study (Fig. S1A). 
2.3. Statistical analysis 
The normality of distribution of fold change values between con-
trols and SZ subjects was analysed with the Kolmogorov-Smirnov
test. The non-parametric Mann–Whitney test was performed to
compare each group when they did not follow a normal distribu-
tion, while the unpaired t-test was used for normal variables. Out-
liers were detected where indicated using Pierce’s criterion (as sim-t al., Neuroinflammation in the dorsolateral prefrontal cortex in 
ps://doi.org/10.1016/j.euroneuro.2018.12.011 
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Table 3 Association analysis with CD68 glial marker. 
CD68 
SZ-C cohort r n 
CSF1R 0.902 a 26 
TLR4 0.543 b 25 
IL6 0.691 a 27 
TNF α 0.812 a 18 
TNFRSF1A 0.752 a 25 
IL10 0.819 a 23 
IL10RA 0.723 a 23 
IL10RB 0.653 a 26 
r, Spearman’s correlation. Significant associations are indicated 
in bold. 
a p < 0.001. 
b p < 0.01. 
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lified by Gould) ( Ross, 2003 ) for non-parametric variables, and
rubbs’ test for parametric variables. The False Discovery Rate 
FDR) with the Benjamini and Hochberg method ( Benjamini and 
ochberg, 1995 ) was computed for all the p -values resulting from
ur study. The FRD threshold was set at 0.1. Bivariate analyses were
arried out to detect association of our variables with potential
onfounding factors (age, post-mortem delay, pH, and RIN; and in
he SZ group, with daily antipsychotic dose, age of onset, and du-
ation of the illness), using Spearman or Pearson correlations for
uantitative variables, for non-parametric variables and for para- 
etric variables, respectively. Multiple linear regression models 
ith a stepwise forward procedure performed after including signif- 
cant related variables were used to adjust significant differences 
hen needed. Statistical analysis was performed with GraphPad 
rism version 5.01 and SPSS 24. The significance level was set at
 < 0.05. 
. Results 
he SZ group did not show significant differences compared 
o the control group in demographic and tissue-related vari- 
bles ( Table 1 ). We analysed the gene expression of cy-
okine modulators (members of the complement system 
 C1QL1, C1QTNF7, C3AR1 ), colony stimulating factor re- 
eptors ( CSF1R, CSF3R ), Toll family ( TLR4, TLR7 )), pro-
nflammatory cytokines (interleukins ( IL1B, IL8, IL6, IL6ST ), 
NF α family ( TNFRSF1A, TNF α)) and anti-inflammatory cy- 
okines ( IL10 family ( IL10, IL10RA, IL10RB ) and TGF β family
 TGF β1, TGF β2 )) in the dorsolateral prefrontal cortex of el-
erly subjects with chronic SZ (n = 14) and controls (n = 14).
PNEP1 gene expression was used to normalize the mRNA 
evels. No differences were observed in XPNPEP1 expression 
etween control and SZ groups (Fig. S1B). Among the cy- 
okine modulators, we found that CSF1R and TLR4 mRNA 
xpression levels were significantly down-regulated in SZ 
ases compared to control subjects ( Fig. 1 ). In the pro-
nflammatory genes, IL6, TNF α, and TNFRSF1A mRNA ex- 
ression levels were significantly decreased in SZ compared 
o control subjects ( Fig. 2 ). Concerning anti-inflammatory 
ytokines, three out of five analysed genes showed signifi- 
ant reduction in SZ compared with controls, including IL10, 
L10RA, and IL10RB ( Fig. 3 ). 
We also investigated the expression levels of microglial 
arkers ( AIF1 and CD68 ) and the astroglial marker GFAP .
o altered expression levels for the astrocyte marker GFAP 
ere found in SZ samples compared to controls. For the mi-
roglial markers AIF1 (which encodes IBA1) and CD68 (reac- 
ive microgliosis), only CD68 mRNA expression levels were 
ignificantly decreased in the dorsolateral prefrontal cortex 
f SZ patients ( Fig. 4 ). 
To further investigate the possible relationship between 
ltered microglial ( CD68 ) and altered inflammatory genes, 
e tested whether there were any associations between 
hem. We found that all the expression levels of the al-
ered inflammatory genes in SZ significantly correlated with 
he microglial marker CD68 ( Table 3 ). In addition, no as-
ociations were found for any significantly altered gene 
ith the severity of negative symptoms measured by PANSS 
Table S1). 
Association analysis of other variables in the study 
age, post-mortem delay, pH, RIN, and AD) revealed only 
n association between pH and TNF α expression levels Please cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, httSpearman r = 0.590, p = 0.010; Table 4 ). Linear regression
nalysis revealed that TNF α remained significant after ad- 
usting for pH ( β = -0.280, p = 0.030, adjusted R 2 = 0.903).
he schizophrenia subgroup analysis showed that daily an- 
ipsychotic dose, type of antipsychotic drug (second gener- 
tion vs. first generation), age of onset and duration of the
llness had no effect on gene expression levels for any of the
enes altered in the study ( Table 4 ). 
Since we were performing multiple comparisons, we cor- 
ected the p -values obtained in the control-schizophrenia 
omparisons for a False Discovery Rate (FDR) of 0.1. All the
ignificant p -values observed in our analyses ( Figs. 1–4 ) were
aintained after correction for an FDR of 0.1 (Table S2). In
ddition, we also corrected p -values for multiple compar-
sons of the association analysis with glia markers. All the
ignificant p -values observed in the correlations were main-
ained after correction (Table S3). 
. Discussion 
 dysfunction of the immune system/neuroinflammatory 
athways has been linked to SZ ( Gibney and Drexhage, 2013;
irkpatrick and Miller, 2013 ). In this study, we have char-
cterized the gene expression of a group of 21 key genes
nvolved in immune homeostasis, including pro- and anti- 
nflammatory cytokines, cytokine modulators (toll-like re- 
eptors, colony-stimulating factors, and members of the 
omplement system) and glial markers in the prefrontal cor-
ex in elderly chronic SZ. The present study reveals that
he cytokine modulators CSF1R and TRL4 , the pro-
nflammatory cytokines IL6, TNF α, and TNFRS1A , the anti-
nflammatory cytokines IL10, IL10RA, and IL10RB , and the
lial marker CD68 are down-regulated in the dorsolat- 
ral prefrontal cortex in aged SZ patients. Moreover, we
ound that all the significantly down-regulated genes cor- 
elated with the expression levels of the glial marker CD68.
hus, this study reveals the alteration of several inflamma-
ory/immune system markers in the dorsolateral prefrontal 
ortex in chronic SZ subjects at advanced age and suggests
hese changes may also be linked to the down-regulation of
 marker for reactive microgliosis. 
Cytokines are produced by various immune and non- 
mmune cells and include chemokines, interleukins, t al., Neuroinflammation in the dorsolateral prefrontal cortex in 
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Fig. 1 mRNA expression levels of cytokine modulators in the dorsolateral prefrontal cortex in control and schizophrenia cases . 
Each individual value represents the mean of fold-change values for each subject for the distinct probes that were determined 
with TaqMan PCR assays and normalized to XPNPEP1 . Mean and standard error of the mean is represented for each group. Mean 
fold-change values for each group were compared with Student’s t -test ( C1QTNF, C3AR1, CSF1R, TLR4, and TLR7 ) or Mann–Whitney 
U test ( C1QL1 and CSF3R ). One outlier for C1QL1, C3AR1, TLR4, and TLR7, and two outliers for CSF3R and C1QTNF7, were detected 
and were excluded from the analysis . One sample did not show detectable levels for C1QTNF7, C3AR1, and CSF1R and three samples 
did not show detectable levels for CSF3R and TLR7 in the SZ group. One sample did not show detectable levels for TLR4 and two 
samples did not show detectable levels for TLR7 in the control group . One sample for CSF3R was not included due to CT duplicate 
differences. Differences in schizophrenia cases versus control cases were considered statistically significant at ∗ p < 0.05. n.s, not 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
interferons, lymphokines, and tumor necrosis factors. There
is an increasing amount of evidence suggesting an immune
system disruption in SZ. Several cytokines have been anal-
ysed in serum and/or plasma, and in post-mortem brain
tissue of SZ patients. High blood and serum levels of pro-
inflammatory cytokines have been reported in schizophre-
nia subjects ( Kunz et al., 2011; Miller et al., 2011; Potvin
et al., 2008; Xu et al., 1994 ); however, a goodly number
of studies included middle-aged subjects with SZ, and lit-
tle is known about possible deregulation of SZ in long-term
treated elderly SZ subjects. In a meta-analysis, peripheral
blood levels of IL1 β, IL6, and TGF β were increased during an
acute relapse and in patients with first-episode psychosis,
suggesting that they might be state markers for acute ex-
acerbations ( Miller et al., 2011 ). In contrast to our results,
the levels of the pro-inflammatory cytokines IL6, IL1 β, IL8,
and TNF α were found to be increased in the prefrontal cor-
tex of middle-aged SZ patients ( Fillman et al., 2013; Pandey
et al., 2018 ), while we found IL6, TNF α and TNFRSF1A to
be reduced in our elderly long-term treated sample. More-
over, increased levels of IL6 have been described in serum
of elderly chronic SZ patients on stable antipsychotic med-
ication, but with shorter duration of the illness (average 35
years) ( Schmitt et al., 2005 ). Also increased levels of TLR4
RNA have been recently reported in the prefrontal cortex in
a cohort of middle age cases of schizophrenia and schizoaf-Please cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, httfective cases ( Volk et al., 2018 ). This result is the oppo-
site of our finding and could be due to a different effect in
middle age patients compared to elderly patients and also
to different regulation of TLR4 expression in schizoaffec-
tive cases. Our results for TLR4 are in agreement with a
recent post-mortem study in a similar, but not identical, co-
hort of elderly chronic schizophrenia patients, where TLR4
protein levels was also found to be down-regulated in the
prefrontal cortex ( MacDowell et al., 2017 ). This suggests
that the changes in mRNA observed for pro-inflammatory
cytokines could be the same at the protein level. Further
studies will be needed to confirm this possibility. Our study
supports an opposite deregulation for these mediators in
patients with long disease duration and long-lasting treat-
ments with antipsychotics at an advanced age. It is not
clear how the advanced age and the long course of the
disease of the cases could offset the initially active pro-
inflammatory cytokine expression reported in other studies
in middle-aged patients. However, long-term antipsychotic
treatments could be responsible for this possible compen-
satory mechanism, resulting in down-regulation of the ex-
pression of these genes over the years of treatment. In this
regard, normalization of increased cytokine levels has been
reported in patients under stable antipsychotic treatment
( Miller et al., 2011 ). This is in line with other studies that
proposed that antipsychotics may exert anti-inflammatoryt al., Neuroinflammation in the dorsolateral prefrontal cortex in 
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Fig. 2 mRNA expression levels of pro-inflammatory cytokines in the dorsolateral prefrontal cortex in control and schizophrenia 
cases. Each individual value represents the mean of fold-change values for each subject for the distinct probes that were determined 
with TaqMan PCR assays and normalized to XPNPEP1 . Mean and standard error of the mean is represented for each group. Mean 
fold-change values for each group were compared with Student’s t -test ( IL8, IL6ST, TNF α, and TNFRSF1A ) or Mann–Whitney U test 
( IL1B and IL6 ). One outlier was detected for IL1B and TNFRSF1A and two outliers were detected for IL8 in the control group. In the 
SZ group, one outlier was detected for IL8, IL1B, and IL6. These outliers were not included in the analysis. One sample did not show 
detectable levels for TNFRSF1A in the SZ group, while four and six samples did not show detectable levels for TNF α in the case and 
control groups, respectively. Differences in schizophrenia cases versus control cases were considered statistically significant at ∗
p < 0.05. n.s, not significant . 
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o  ffects ( Müller, 2017; Tourjman et al., 2013 ). Although in
ur study in elderly patients we did not find an association
etween the last antipsychotic prescription and our molec- 
lar measures, the cases of this study were institutional- 
zed patients under long-lasting antipsychotic medications 
ith a high rate of treatment adherence. This raises the
ossibility that these treatments with antipsychotics over 
he years could be responsible for the down-regulation of 
ro-inflammatory cytokines observed in our study. It is also 
ossible that the suicide component of the cohorts used in 
ther studies might have contributed to the different re- 
ults observed in this study. Our study included subjects that
ied of natural causes while other studies were carried out
n cohorts that included subjects that committed suicide 
 Fillman et al., 2013; Pandey et al., 2018; Schmitt et al.,
005 ). Further studies in aged SZ patients are needed to in-
estigate the influence of antipsychotics and the mechanism 
f death on the expression of immune and inflammatory 
ediators. 
Our study also examined the anti-inflammatory cytokines 
L10, IL10RA, IL10RB, TGFB1, and TGFB2 and found that the
nterleukin IL10 and its receptors IL10RA and IL10RB were 
own-regulated in the dorsolateral prefrontal cortex in SZ 
ubjects. An increase in IL10 in blood has been reported in
rst-episode psychosis ( Goldsmith et al., 2016 ); however, Please cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, htt decrease in IL10 has also recently been reported in pre-
rontal cortex in schizophrenia ( Pandey et al., 2018 ), while
 recent meta-analysis also showed a decrease in blood IL10
n both acutely and chronically ill patients with schizophre-
ia ( Goldsmith et al., 2016 ). Thus, our results in elderly pa-
ients seem to be in line with previous reports on this disor-
er with younger cohorts, in which an initial up-regulation
f the anti-inflammatory cytokine IL10 in the disorder seems 
o be followed by a later down-regulation in the periphery
nd also in the brain. 
Our results for microglial markers indicate that there is a
ecrease in the expression of the CD68 gene in the dorso-
ateral prefrontal cortex in elderly SZ subjects, which posi-
ively correlated with the altered cytokines and their modu-
ators. This is in line with a previous post-mortem study that
howed a correlation between the stage of activation of mi-
roglia and the expression levels of the pro-inflammatory 
ytokine IL1B in the same region in middle-aged patients
ith schizophrenia ( Fillman et al., 2013 ). The reduction ob-
erved in CD68 could be due to the long-lasting antipsy-
hotic treatments of these patients, since a decrease in
his marker has recently been reported in monocytes upon
reatment with antipsychotics ( Bahramabadi et al., 2017 ).
lternatively, the reduction observed could be the result 
f a lower density of microglia in tissue in these patients.t al., Neuroinflammation in the dorsolateral prefrontal cortex in 
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Fig. 3 mRNA expression levels of anti-inflammatory cytokines in the dorsolateral prefrontal cortex in control and schizophrenia 
cases. Each individual value represents the mean of fold-change values for each subject for the distinct probes that were determined 
with TaqMan PCR assays and normalized to XPNPEP1 . Mean and standard error of the mean is represented for each group. Mean 
fold-change values for each group were compared with Student’s t -test. One outlier was detected in the control group for TGFB1 
and in the SZ group for IL10, TGFB1, IL10RA, and IL10RB, and these were not included in the analysis . One and two samples did not 
show detectable levels for IL10RA and IL10 in the control and case groups, respectively. Differences in schizophrenia cases versus 
control cases were considered statistically significant at ∗ p < 0.05.; n.s, not significant. 
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Fig. 4 mRNA expression levels of glial markers in the dorsolateral prefrontal cortex in control and schizophrenia cases. Each 
individual value represents the mean of the expression gene values for each subject for the distinct probes that were determined 
with TaqMan PCR assays and normalized to XPNPEP1 . Mean and standard error of the mean is represented for each group. Mean 
fold-change values for each group were compared with Student’s t -test ( CD68 and AIF1 ) or Mann–Whitney U test ( GFAP ). One sample 
in the SZ group did not show detectable levels for the 3 genes. Two outliers were detected in the control group for GFAP and were 
not included in the analysis. Differences in schizophrenia cases versus control cases were considered statistically significant at ∗
p < 0.05 . n.s, not significant . 
 
 
 
 
 
 
 
 
 
 
However, the AIF1 gene expression (a pan-microglia maker)
was not altered in our study, suggesting that a global reduc-
tion of microglia may not be occurring in the DLPFC in el-
derly schizophrenia. CD68 gene encodes for a lysosomal pro-
tein which is up-regulated in actively phagocytic microgliaPlease cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, htt( Zotova et al., 2013 ), raising the possibility that there might
be a reduction in the more phagocytically active microglia
subpopulation in these patients. Microglial activation and an
increase in microglial cells in the brain of SZ patients have
been reported in mostly chronic middle-age post-mortemt al., Neuroinflammation in the dorsolateral prefrontal cortex in 
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Table 4 Association analysis of other variables in the study. 
SZ-C cohort 
n Age PMD pH RIN AD 
CSF1R 27 −0.053 a 0.024 a 0.254 a −0.033 a 0.074 a 
TLR4 26 −0.082 b 0.255 b −0.109 −0.030 b 0,014 b 
IL6 27 −0.168 a 0.058 a 0.276 a 0.157 a −0.071 a 
TNF α 18 0.017 a -0.002 a 0.590 a −0.060 a 0.120 a 
TNFRSF1A 26 0.092 a 0.070 a 0.128 a 0.019 a −0.081 a 
IL10 24 −0.001 a 0.043 a 0.394 a 0.011 a 0.242 a 
IL10RA 24 0.195 a 0.132 a 0.193 a 0.299 a 0.174 a 
IL10RB 27 −0.111 a 0.209 a −0.053 a −0.224 a 0.350 a 
CD68 27 −0.191 a 0.126 a 0.170 a 0.030 a −0.020 a 
SZ cohort 
n Daily AP dose ‡ Age of Onset Duration of illness 
CSF1R 13 0.323 b −0.215 a 0.165 b 
TLR4 14 0.345 b −0.006 a 0.102 b 
IL6 13 0.156 b −0.061 a −0.104 b 
TNF α 8 −0.040 b 0.024 a −0.290 b 
TNFRSF1A 13 0.048 b 0.173 a 0.232 b 
IL10 11 0.088 b −0.200 a 0.273 b 
IL10RA 11 −0.101 b 0.317 a 0.127 b 
IL10RB 13 0.392 b −0.437 a 0.330 b 
CD68 13 0.345 b −0.291 a −0.254 b 
a Spearman’s correlation for non-parametric variables; 
b Pearson’s r for parametric variables; PMD, post-mortem delay; RIN, RNA integrity number; AP, antipsychotic; AD, histological stage of 
Alzheimer disease as described previously ( Braak et al., 2006; Braak and Braak, 1991 ). Significant associations ( p < 0.05) are indicated in 
bold. 
‡ Last chlorpromazine equivalent dose was calculated based on the electronic records of drug prescriptions of the patients. Comparison of 
mRNA levels was performed between patients under first-generation and second-generation antipsychotic medication with the exception of 
IL10 and IL10RB, for which there were not enough determinations for this analysis. No significant differences were found (data not shown). 
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t  tudies ( Bayer et al., 1999; Busse et al., 2012; Radewicz
t al., 2000; van Kesteren et al., 2017; Wierzba-Bobrowicz 
t al., 2005 ). This process has been reported to be influ-
nced by some clinical features and by the mechanism of
eath ( Laskaris et al., 2016 ). One study found an increase
n microglial density in middle-aged patients with para- 
oid schizophrenia versus non-acute schizophrenia patients 
 Busse et al., 2012 ). Increased microglial density could also
e the result of a violent death of the patients, since an
ncreased number of activated microglia in the dorsolateral 
refrontal cortex has been reported in patients who com- 
itted suicide during acute psychosis ( Busse et al., 2012; 
teiner et al., 2008, 2006 ). However, the patients included 
n our study were mainly non-acute schizophrenia patients 
ho died of natural causes; thus an increased activation of
icroglia seems unlikely in these patients. 
Although neuroinflammation is characterized by the ac- 
ivation of microglial cells, astrocytes also play an impor- 
ant role ( Chavarria and Alcocer-Varela, 2004 ). Expression 
evels for the astrocyte marker GFAP did not differ among 
he groups in our study, although previous studies have re-
orted a decrease or no change in GFAP mRNA expression 
 Barley et al., 2009; Katsel et al., 2011; Trépanier et al.,
016; Webster et al., 2005 ). A similar situation also occurred
ith GFAP protein; studies have reported decreased, simi- 
ar, or increased levels in schizophrenia patients depending 
n the brain region examined ( Arnold et al., 1996; SteffekPlease cite this article as: I. López-González, R. Pinacho and È. Vila e
elderly chronic schizophrenia, European Neuropsychopharmacology, httt al., 2008; Toro et al., 2006; Trépanier et al., 2016 ). A
ecent study found evidence of astrogliosis (mRNA and pro-
ein) in a subset of patients with schizophrenia and high ex-
ression of inflammatory markers ( Catts et al., 2014 ), sug-
esting that the differences in previous studies were due to
ohort differences in illness stage, exposure to treatment, 
r a failure to consider subsets of subjects with SZ. 
The use of human post-mortem tissue allows for the
olecular dissection of possible disrupted pathways in psy- 
hiatric disorders, but it presents limitations that have to be
onsidered. First, the potential effect of possible confound- 
ng factors, including age, gender, post-mortem delay, his- 
ological degree of Alzheimer’s disease, pH, and RIN has to
e carefully explored. These factors have been controlled 
or and their potential influence ruled out in our study. Sec-
nd, the patients included in our study were taking long-
asting and heterogeneous antipsychotic medications. To 
ontrol for this variable, we used the last daily chlorpro-
azine equivalent dose, calculated as reported previously 
 Gardner et al., 2010 ), in a bivariate analysis ( Table 4 ).
he last daily chlorpromazine equivalent dose had no effect
n the variables studied here ( Table 4 ). We also searched
or differences in our molecular measures between patients 
nder first and second generation antipsychotics. We did 
ot find any differences between the two groups. How-
ver, larger sample size is required to increase the sta-
istical power of those analyses. Third, since some of thet al., Neuroinflammation in the dorsolateral prefrontal cortex in 
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pro-inflammatory cytokines in this study (IL6, IL1B ) have
been previously described as increased in frontal cortex of
AD grade I and II ( López-González, I. et al., 2015b ), initial
histological stages of Alzheimer disease (AD) might also have
influenced our results. Here we report down-regulation of
IL-6 instead of the increase reported in low degree AD. Our
group of cases was matched with a control group also tak-
ing into account the histological degree of AD (0-III, low
degree). In addition, no associations were found between
histological AD stage and our molecular measures (data not-
shown). Fourth, the study only included men. Fifth, a care-
ful interpretation should be made of the negative results
of our study, which could be the result of limited statisti-
cal power rather than the lack of alteration in schizophre-
nia. Sixth, institutionalization of cases could have also in-
fluenced our findings. Therefore, further studies with larger
cohorts of aged subjects with equal representation of both
genders, and, if possible, non-institutionalized, drug naïve
patients would be of interest. Despite these limitations, the
findings from this study may contribute towards better un-
derstanding of the role of the immune/inflammatory sys-
tems in schizophrenia at an advanced age. 
Taken together, our findings show a decrease in the ex-
pression of cytokine and inflammation mediators in the dor-
solateral prefrontal cortex of subjects with elderly chronic
SZ. Thus, the results reported here further suggest that
a dysfunction of the immune system/neuroinflammation
pathways is possibly linked with the abundance of active
microglia that may be contributing to mechanisms that are
altered in the dorsolateral prefrontal cortex in an elderly
population with chronic SZ. 
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